In the standards of diabetes care-2024 by the ADA, it is recommended that the treatment of adult T2DM patients with cardiovascular or/and renal risk should include SGLT2i and/or GLP-1 Ras [115]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.